PMID: 8939644Dec 1, 1996Paper

T-cell gene therapy

Current Opinion in Biotechnology
K M Hege, M R Roberts

Abstract

In the past year, a number of human gene therapy trials involving the adoptive transfer of genetically modified T lymphocytes have been reported. These include trials of adenosine deaminase gene transfer in children with severe combined immunodeficiency syndrome, a gene-marking study of Epstein-Barr virus-specific cytotoxic T cells, and trials of gene-modified T cells expressing suicide or viral resistance genes in patients infected with HIV. Additional strategies for T-cell gene therapy currently being pursued in the clinic involve the engineering of novel T-cell receptors that impart antigen specificity for virally infected or malignant cells.

Citations

Sep 21, 2000·Leukemia Research·O AfonjaK Takeshita
Dec 24, 1997·Cancer Genetics and Cytogenetics·K F WongC C So
Oct 20, 1999·Cancer Genetics and Cytogenetics·F MarcoA Zubizarreta
Nov 24, 1999·Cancer Genetics and Cytogenetics·K F WongY L Kwong
Mar 13, 2010·Human Gene Therapy·Raymond T DotyJanis L Abkowitz
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·M C JensenA Raubitschek
Jul 29, 2003·Gene Therapy·S OkanoK Sueishi
Oct 19, 2002·Oncogene·Michele ModugnoSylvie Ménard

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.